Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 6/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.45 |
| ▸ | CDK8 | P49336 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1662655 | 0.84 | AR (0.51) | ARCYP3A4TSHRKMT2AALDH1A1 | |
| SCHEMBL12438322 | 0.84 | MAPK1 (0.44) | ARSMN1; SMN2CYP3A4TSHRLMNA | |
| Hydrochloric Acid SCHEMBL6151019 | 0.82 | AR (0.50) | ARCYP3A4TSHRKMT2AALDH1A1 | |
| SCHEMBL2399432 | 0.82 | ALDH1A1 (0.43) | ARSMN1; SMN2CYP3A4TSHRLMNA | |
| SCHEMBL5750827 | 0.82 | AR (0.40) | ARSMN1; SMN2CYP3A4TSHRLMNA | |
| SCHEMBL4348433 | 0.81 | KDM4E (0.41) | ARSMN1; SMN2CYP3A4LMNAKMT2A | |
| SCHEMBL27520536 | 0.81 | AR (0.39) | ARSMN1; SMN2CYP3A4TSHRLMNA | |
| SCHEMBL1299113 | 0.80 | SMN1; SMN2 (0.48) | ARSMN1; SMN2CYP3A4TSHRSIRT2 | |
| SCHEMBL1842086 | 0.79 | KMT2A (0.43) | ARSMN1; SMN2LMNAKMT2AALDH1A1 | |
| SCHEMBL2388875 | 0.79 | MEN1 (0.44) | ARSMN1; SMN2KMT2AALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9949970-B2 | Synthesis of new benzothiazole derivatives as potential anti-tubercular agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | claimed |
| US-20160175303-A1 | SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-06-23 | — | — | US | claimed |
| US-20120095021-A1 | SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2012-04-19 | — | — | US | claimed |
| CN-101723872-B | Symmetric conjugate of polyamine and pyrrolepolyamide and preparation method thereof | UNIV SOUTHERN MEDICAL | 2011-09-14 | — | — | CN | claimed |
| CN-101723872-A | Symmetric conjugate of polyamine and pyrrolepolyamide and preparation method thereof | UNIV SOUTHERN MEDICAL | 2010-06-09 | — | — | CN | claimed |
| US-9949970-B2 | Synthesis of new benzothiazole derivatives as potential anti-tubercular agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2018-04-24 | — | — | US | disclosed |
| US-20160175303-A1 | SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-06-23 | — | — | US | disclosed |
| CN-102666545-B | As the heterocycle Pyrazolopyrimidine analogs of JAK inhibitor | CELLZOME LTD. (GB) | 2016-04-06 | — | — | CN | disclosed |
| US-9273039-B2 | Synthesis of new benzothiazole derivatives as potential anti-tubercular agents | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2016-03-01 | — | — | US | disclosed |
| CN-102666545-A | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors | CELLZOME LTD | 2012-09-12 | — | — | CN | disclosed |
| US-20120095021-A1 | SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH | 2012-04-19 | — | — | US | disclosed |
| CN-101723872-B | Symmetric conjugate of polyamine and pyrrolepolyamide and preparation method thereof | UNIV SOUTHERN MEDICAL | 2011-09-14 | — | — | CN | disclosed |
| CN-101723872-A | Symmetric conjugate of polyamine and pyrrolepolyamide and preparation method thereof | UNIV SOUTHERN MEDICAL | 2010-06-09 | — | — | CN | disclosed |
| EP-1020446-B1 | NAPHTHALIMIDOBENZAMIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO LTD (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | TAISHO PHARMACEUTICAL CO., LTD. | 2005-09-08 | — | — | US | disclosed |
| US-6300331-B1 | DRUGS AS ANTITUMOR AGENTS OR ANTICARCINOGENIC AGENTS | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-09 | — | — | US | disclosed |
| EP-1020446-A1 | NAPHTHALIMIDOBENZAMIDE DERIVATIVES | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160175303-A1 | SYNTHESIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS | TST, TBCA, SDHA | AR 4255/4885SMN1; SMN2 4865/4885CYP3A4 756/4885 |
| US-20120095021-A1 | SYNTHSIS OF NEW BENZOTHIAZOLE DERIVATIVES AS POTENTIAL ANTI-TUBERCULAR AGENTS | TST, SDHB, SDHA | AR 4475/4885SMN1; SMN2 3952/4885CYP3A4 1175/4885 |
| US-20050197350-A1 | Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof | HCRTR2, MCHR1, MCHR2 | AR 4067/4885SMN1; SMN2 1477/4885CYP3A4 284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.